Dr. Yardley on HERMIONE-2 Trial for HER2+ Breast Cancer
Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in patients with anthracycline-naive HER2-positive, locally advanced/metastatic breast cancer who were previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).
Denise A. Yardley, MD, senior investigator, Breast Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the phase II HERMIONE-2 trial, which is a randomized, open-label trial comparing MM-302 plus trastuzumab (Herceptin) with chemotherapy plus trastuzumab in patients with anthracycline-naïve, locally advanced, HER2-positive breast cancer who were previously treated with pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1).
This ongoing trial is addressing an unmet need, as there is a rising incidence of HER2-positive patients who are anthracycline-naive, Yardley explains. In the study, patients in the MM-302 arm receive the novel antibody-drug conjugate once every 3 weeks.
The primary endpoint of the study, she adds, is progression-free survival. The safety of MM-302 in combination with trastuzumab will also be explored.
